Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115118) titled 'Clinical Study on the Improvement of Immune Status in Primary Liver Cancer PLC Patients after TACE by ß-1,3/a-1,3-Glucan' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First People's Hospital of Qinzhou
Condition:
primary liver cancer
Intervention:
Control group:Targeted immunotherapy after TACE
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-29
Target Sample Size: Control group:20;ß-1,3/a-1,3-glucan experimental group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj...